Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 1995;26:1365-1368

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nagao, T.
Right arrow Articles by Terashi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagao, T.
Right arrow Articles by Terashi, A.

(Stroke. 1995;26:1365-1368.)
© 1995 American Heart Association, Inc.


Articles

Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation

Takehiko Nagao, MD; Makoto Hamamoto, MD; Akemi Kanda, MD; Toshikazu Tsuganesawa, MD; Masayuki Ueda, MD; Katsushi Kobayashi, MD; Tokuzou Miyazaki, MD Akiro Terashi, MD

From the Department of Neurology, Tokyo Metropolitan Tama Geriatric Hospital (T.N., M.H., M.U., K.K., T.M.), and the Second Department of Internal Medicine, Nippon Medical School (A.K., T.T., A.T.), Tokyo, Japan.

Correspondence to Takehiko Nagao, MD, Department of Neurology, Tokyo Metropolitan Ebara Hospital, 4-5-10 Higashi-Yukigaya, Ohta-ku, Tokyo 145, Japan.

Background and Purpose It is generally accepted that the coagulation system is activated in ischemic stroke and that platelet activation is involved in the pathogenesis of this disease. However, little is known about how and to what extent platelet activity participates in coagulation system enhancement. We evaluated the hemostatic condition, especially with regard to platelet function and the coagulation system, within 3 days of onset of acute stroke. The study participants were limited to elderly patients with cardioembolic stroke due to nonvalvular atrial fibrillation.

Methods Seventeen elderly patients with acute cardioembolic stroke due to nonvalvular atrial fibrillation were investigated. Within 3 days of stroke onset, ß-thromboglobulin (BTG), platelet factor 4 (PF4), thrombin-antithrombin III complex (TAT), and D-dimer from arterial blood were carefully evaluated in these patients. Blood samples from 19 healthy age- and sex-matched control subjects were also examined.

Results The two studied markers of platelet activity did not change in the patients or the control subjects, and the between-group differences between the stroke and control groups were not statistically significant (BTG, 43.8 versus 31.9 ng/mL; PF4, 9.06 versus 5.78 ng/mL; respectively). In contrast, the two studied coagulation-system indicators were markedly elevated in the patients compared with the control subjects (TAT, 13.8 versus 3.5 ng/mL, P<.01; D-dimer, 366.3 versus 147.2 ng/mL, P<.01; respectively).

Conclusions Platelet function was not enhanced in the acute stage of cardioembolic stroke with nonvalvular atrial fibrillation. This result indicates that enhancement of the coagulation system in cardioembolic stroke is not the result of platelet hyperfunction, ie, "platelet-fibrin" thrombi, but rather of "stasis-related" thrombi formation.


Key Words: atrial fibrillation • blood coagulation disorders • cardioembolic stroke • platelet activation




This article has been cited by other articles:


Home page
StrokeHome page
J. Montaner, M. Perea-Gainza, P. Delgado, M. Ribo, P. Chacon, A. Rosell, M. Quintana, M. E. Palacios, C. A. Molina, and J. Alvarez-Sabin
Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers
Stroke, August 1, 2008; 39(8): 2280 - 2287.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
H. J. Kim and R. Arora
Emerging Role of Direct Thrombin Inhibitors in Nonvalvular Atrial Fibrillation: Potential and Peril
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2005; 10(1): 11 - 21.
[Abstract] [PDF]


Home page
CirculationHome page
C. Stollberger, B. Schneider, J. Finsterer, H. Sievert, T. Trepels, D. Fleschenberg, U. Krumsdorf, D. Scherer, M. D. Lesh, T. Nakai, et al.
Is Percutaneous Left Atrial Appendage Transcatheter Occlusion an Alternative to Oral Anticoagulation in Patients With Atrial Fibrillation? * Response
Circulation, January 7, 2003; 107 (1): e11 - e12.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S. Kamath, A. D. Blann, B. S. P. Chin, F. Lanza, B. Aleil, J. P. Cazenave, and G. Y. H. Lip
A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy
Eur. Heart J., November 2, 2002; 23(22): 1788 - 1795.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S. Kamath, A.D. Blann, and G.Y.H. Lip
Platelets and atrial fibrillation
Eur. Heart J., December 2, 2001; 22(24): 2233 - 2242.
[PDF]


Home page
StrokeHome page
Y. Fujii, S. Takeuchi, A. Harada, H. Abe, O. Sasaki, and R. Tanaka
Hemostatic Activation in Spontaneous Intracerebral Hemorrhage
Stroke, April 1, 2001; 32(4): 883 - 890.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. L. Li-Saw-Hee, A. D. Blann, and G. Y. H. Lip
A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation
J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1926 - 1931.
[Abstract] [Full Text] [PDF]